GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Price-to-Tangible-Book

Shanghai Henlius Biotech (HKSE:02696) Price-to-Tangible-Book : (As of May. 28, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Price-to-Tangible-Book?

As of today (2025-05-28), Shanghai Henlius Biotech's share price is HK$43.80. Shanghai Henlius Biotech's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was HK$-4.60. Hence, Shanghai Henlius Biotech's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Shanghai Henlius Biotech's Price-to-Tangible-Book or its related term are showing as below:

During the past 8 years, Shanghai Henlius Biotech's highest Price to Tangible Book Ratio was 83.54. The lowest was 10.90. And the median was 47.22.

HKSE:02696's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.71
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Shanghai Henlius Biotech's share price is HK$43.80. Shanghai Henlius Biotech's Book Value per Sharefor the quarter that ended in Dec. 2024 was HK$5.92. Hence, Shanghai Henlius Biotech's P/B Ratio of today is 7.40.


Shanghai Henlius Biotech Price-to-Tangible-Book Historical Data

The historical data trend for Shanghai Henlius Biotech's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Price-to-Tangible-Book Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Tangible-Book
Get a 7-Day Free Trial 83.54 - - - -

Shanghai Henlius Biotech Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Shanghai Henlius Biotech's Price-to-Tangible-Book

For the Biotechnology subindustry, Shanghai Henlius Biotech's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Price-to-Tangible-Book falls into.


;
;

Shanghai Henlius Biotech Price-to-Tangible-Book Calculation

Shanghai Henlius Biotech's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2024 )
=43.80/-4.6
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Shanghai Henlius Biotech Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech Business Description

Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Ubs Group Ag
Golden Valley Value Select Master Fund 2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Lvc Sg Management Pte. Ltd. 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lin Lijun 2201 Interest of corporation controlled by you
Qatar Investment Authority 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines